avelumab

Ligand id: 8735

Name: avelumab

No information available.
Summary of Clinical Use
Avelumab was FDA approved in March 2017 (under the FDA's accelerated approval program), and by the EMA in August 2017. Both approvals are for the treament of Merkel cell carcinoma (MCC; a rare and aggressive type of skin cancer) in adults and children >12 years old. In May 2017, FDA accelerated approval was also granted for the treatment of locally advanced or metastatic urothelial carcinoma (that has progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy). It has been granted orphan status by the EMA (December 2016) for gastric cancer. A Phase III clinical trial in non-small cell lung cancer (NSCLC) is ongoing.
Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug's mechanism of action enables immune cells to detect and destroy tumour cells.